Browse Studies — Arctuva

Real-World Utilization, Treatment Patterns, Tolerability, and Effectiveness of Zanidatamab in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma in the United States

The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and …

Esophageal CancerGastroEsophageal CancerGastroesophageal-junction Cancer+2 more

Estimated

~$10 – $1,050

Jazz PharmaceuticalsNCT07780968

Phase 3

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination …

HER2-positive Gastric CancerGastroesophageal Junction Adenocarcinoma

Estimated

~$10 – $7,500

AstraZenecaNCT06764875

Phase 1

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

Estimated

~$10 – $8,750

Mersana TherapeuticsNCT05514717

Phase 3

A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with t…

Gastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer+1 more

Estimated

~$10 – $8,750

Shanghai Henlius BiotechNCT06532006